Measuring fidelity to delivery of a new smoking cessation intervention integrated into routine tuberculosis care in Pakistan and Bangladesh:contextual difference and opportunities

• Boeckmann, Melanie
• Dogar, Omara https://orcid.org/0000-0002-7122-8403
• Saeed, Saima
• Majidulla, Arman
• Swami, Shilpi https://orcid.org/0000-0002-7537-8636
• Khan, Amina
• Siddiqi, Kamran https://orcid.org/0000-0003-1529-7778
• Kotz, Daniel

Funding Information: The authors have each completed and submitted an ICMJE form for disclosure of potential conflicts of interest. The authors declare that they have no competing interests, financial or otherwise, related to the current work. K. Siddiqi reports grants from European Commission H2020, and non-financial support from Aflofarm, during the conduct of the study. D. Kotz reports that he received an unrestricted grant from Pfizer in 2009 for an investigator-initiated trial on the effectiveness of practice nurse counselling and varenicline for smoking cessation in primary care (Dutch Trial Register NTR3067; DOI: 10.1111/add.13927). Funding Information: The TB & Tobacco project received funding from the European Union’s Horizon 2020 Research and Innovation programme, under Grant Agreement No. 680995. The European Commission is not responsible for the contents of this article. The authors have not entered into an agreement with the funder that may have limited their ability to complete the research as planned. The authors had full control of all primary data. The funding body had no role in design of the study and collection, analysis, and interpretation of data and in writing the manuscript. Aflofarm Pharma Poland provided cytisine and placebo for the trial free of charge. The provider of cytisine had no role in designing or conducting the study, or in preparing this manuscript. Funding Information: The authors thank all the study participants who gave consent to have the behavior support session recorded. We acknowledge the important work of Maryam Noor, Saleem, Sheryar, Fariza Fieroze and Lina Silwa who coded the fidelity indices. Dominic Hart entered data for Bangladesh. We thank Helen Elsey and Sahil Warsi for giving input to first drafts of the fidelity index. The work was conducted while MB was based at the Medical Faculty of the Heinrich-Heine-University Duesseldorf, Institute of General Practice, Addiction Research and Epidemiology Unit. We would like to acknowledge Anne Readshaw for proofreading the manuscript. The TB & Tobacco project received funding from the European Union's Horizon 2020 Research and Innovation programme, under Grant Agreement No. 680995. The European Commission is not responsible for the contents of this article. The authors have not entered into an agreement with the funder that may have limited their ability to complete the research as planned. The authors had full control of all primary data. The funding body had no role in design of the study and collection, analysis, and interpretation of data and in writing the manuscript. Aflofarm Pharma Poland provided cytisine and placebo for the trial free of charge. The provider of cytisine had no role in designing or conducting the study, or in preparing this manuscript. © 2021 Boeckmann M. et al.

• Accepted: 4 February 2021
• Published: 1 April 2021

• http://www.scopus.com/inward/record.url?...